By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syros Pharmaceuticals 

480 Arsenal Street
Suite 130
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-744-1340 Fax: n/a


We are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.

Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.

Key Statistics

Ownership: Private

Web Site: Syros Pharma


Company News
Syros Pharma Reports Second Quarter 2017 Financial Results And Highlights Accomplishments And Upcoming Milestones 8/10/2017 7:32:50 AM
Syros Pharma Publishes Foundational Data Supporting Ongoing Phase II Clinical Trial Of SY-1425 For Genomically Defined AML And MDS Patients 7/21/2017 7:12:25 AM
Syros Pharma Presents Data At EHA Supporting Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients 6/23/2017 7:07:15 AM
Syros Pharma Presents Discovery Of Key Genes Controlling The Autoimmune Response In Lupus In Late-Breaking Oral Presentation At FOCIS Meeting 6/19/2017 8:34:34 AM
Syros Pharma Appoints Srinivas Akkaraju To Its Board Of Directors 6/12/2017 6:26:05 AM
Syros Pharma To Present On SY-1425 In Combination With Standard-of-Care And Targeted Therapies In Genomically Defined Subsets Of AML And MDS Patients 5/18/2017 9:12:27 AM
Syros Pharma Reports First Quarter 2017 Financial Results And Highlights Accomplishments And Upcoming Milestones 5/16/2017 7:38:04 AM
Syros Pharma Announces First Patient Dosed In Phase I Clinical Trial Of SY-1365, Its First-In-Class Selective CDK7 Inhibitor, In Patients With Advanced Solid Tumors 5/15/2017 8:46:36 AM
Syros Pharma Announces Late-Breaking Oral Presentation On Its Research Identifying Key Genes That Control The Auto-Immune Response In Lupus At FOCIS Meeting 5/9/2017 6:49:03 AM
Syros Pharma Presents New Insights On Mechanism Of Action Of SY-1425, Its First-In-Class Selective RARa Agonist, In Oral Plenary Session At AACR Hematologic Malignancies Conferencee 5/8/2017 7:56:27 AM